Cannabis Use Disorder
A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evidence on what actually helps.
Cannabis use disorder is real, it is not the same as 'reefer madness,' and it is not the same as harmless daily use. Roughly 10% of users and up to 30% of daily users meet criteria at some point. The honest part nobody likes: there is no FDA-approved medication for CUD, behavioral therapies work but modestly, and the legalization-era cannabis industry has almost no incentive to talk about this. Withdrawal is real, usually mild-to-moderate, and resolves in 1–2 weeks.
Not medical advice
This article is informational and is not medical advice. It does not replace evaluation by a qualified clinician. If you are trying to cut down or stop and are struggling, or if you are experiencing severe withdrawal, mental health symptoms, or thoughts of self-harm, contact a healthcare provider. In the US you can also call or text 988 (Suicide & Crisis Lifeline) or SAMHSA's helpline at 1-800-662-4357.
Plain-language summary
Cannabis use disorder (CUD) is a clinical diagnosis describing a pattern of cannabis use that causes significant impairment or distress. It's defined in the DSM-5 by 11 criteria (tolerance, withdrawal, using more than intended, failed attempts to cut down, cravings, role failure, interpersonal problems, giving up activities, hazardous use, continued use despite problems, and needing larger amounts) Strong evidence[1].
Meeting 2–3 criteria is mild, 4–5 moderate, 6+ severe. About 10% of people who ever try cannabis develop CUD; the rate climbs to roughly 30% among daily users, and is higher in people who start in adolescence Strong evidence[2][3].
CUD is treatable. It is also frequently underdiagnosed, partly because clinicians, patients, and the cannabis industry have all gotten comfortable framing cannabis as 'not addictive' — a claim that is technically wrong and clinically unhelpful.
What probably works (stronger evidence)
Behavioral therapies, especially in combination. A Cochrane review of 23 randomized trials concluded that cognitive behavioral therapy (CBT), motivational enhancement therapy (MET), and contingency management (CM) reduce frequency and severity of cannabis use, with the largest effects when CBT/MET are combined and delivered for at least four sessions Strong evidence[4].
- CBT + MET (combined): Best-supported package. Typical effect sizes are modest (Cohen's d ~0.3–0.5) but consistent across trials.
- Contingency management: Paying people (via vouchers or prizes) for cannabis-negative urine screens reliably reduces use during the intervention period. Effects shrink after incentives stop Strong evidence[4].
- Brief interventions in primary care reduce use in non-treatment-seeking users, though effects are small Weak / limited[5].
None of these are miracle cures. Abstinence rates at 6–12 months in good trials are commonly in the 15–40% range, which is similar to outcomes for other substance use disorders.
What might work (weak or emerging evidence)
Pharmacotherapy. No medication is FDA-approved for CUD. Several have been studied with mixed or modest results:
- N-acetylcysteine (NAC): A positive adolescent trial (2012) was not replicated in a larger adult/adolescent multisite trial (2017) Disputed[6][7].
- Gabapentin: One small trial showed reduced use and withdrawal; not replicated at scale Weak / limited[8].
- Cannabinoid agonist substitution (dronabinol, nabilone, nabiximols): Reduces withdrawal symptoms reliably; effects on actual abstinence are smaller and inconsistent. Nabiximols (Sativex) has the strongest signal but is not available in the US Weak / limited[9].
- CBD: A Phase 2a UK trial (Freeman et al., 2020) found 400 mg and 800 mg daily CBD reduced cannabis use vs placebo over 4 weeks. Promising but single-trial, short-duration Weak / limited[10].
- Topiramate, bupropion, SSRIs, atomoxetine, naltrexone: Tested, generally disappointing Weak / limited[9].
Digital and app-based CBT: Reasonable convenience play, modest effects, growing literature Weak / limited.
Mindfulness-based relapse prevention: Plausible mechanism, limited cannabis-specific data Weak / limited.
What doesn't work or has weak evidence
- 'Switching to a sativa' or low-myrcene strains. The indica vs sativa framework does not predict effects, and there is no evidence it helps CUD. This is marketing folklore No data.
- Switching to CBD-dominant flower as harm reduction. Plausible in theory, almost no controlled data, and people often add THC back in Weak / limited.
- Cold-turkey willpower alone. Works for some people, but treatment-seeking populations have generally already tried this and failed. Structured support outperforms 'just stop' Strong evidence[4].
- 12-step (Marijuana Anonymous) as standalone treatment. Helpful socially for some; very limited controlled outcome data specific to cannabis Weak / limited.
- Acupuncture, homeopathy, detox teas, ibogaine for cannabis. No credible evidence No data.
What we don't know
- Whether high-potency concentrates (>70% THC) cause meaningfully higher CUD rates than flower at the individual level — population-level signals exist but causal data are thin Weak / limited[11].
- Whether CBD is genuinely useful for CUD, or whether the Freeman 2020 result will replicate.
- Optimal duration and dose for cannabinoid agonist taper (analogous to nicotine replacement).
- How to identify, before someone develops CUD, who is at high genetic or psychiatric risk.
- Whether psychedelic-assisted therapy (psilocybin, ibogaine) has any role. Currently anecdote-level for cannabis specifically Anecdote.
Comparison with other substance use disorders
CUD treatment lags behind alcohol, opioid, and tobacco use disorders, which all have FDA-approved medications (naltrexone/acamprosate, buprenorphine/methadone, varenicline/NRT respectively).
| Disorder | FDA meds | Behavioral evidence | Withdrawal severity | |---|---|---|---| | Opioid | Strong (3 meds) | Strong | Severe, not life-threatening | | Alcohol | Strong (3 meds) | Strong | Can be life-threatening | | Tobacco | Strong (multiple) | Strong | Moderate | | Cannabis | None | Moderate | Mild–moderate, not dangerous |
Cannabis withdrawal — irritability, sleep disruption, decreased appetite, anxiety, restlessness — is real, well-characterized, and was formally added to DSM-5 in 2013 Strong evidence[1][12]. It is not medically dangerous in the way alcohol or benzodiazepine withdrawal can be, but it routinely drives relapse.
Risks and why this matters
CUD is associated with increased risk of:
- Worse outcomes in psychotic disorders and possibly increased risk of incident psychosis in vulnerable users, especially with high-potency products and adolescent onset Strong evidence[13].
- Cannabinoid hyperemesis syndrome in chronic heavy users Strong evidence.
- Cognitive effects (attention, learning) that largely but not entirely resolve with sustained abstinence Strong evidence[14].
- Cardiovascular events in older or at-risk users Weak / limited.
- Occupational, academic, and relationship impairment.
The practical takeaway: most cannabis users do not develop CUD, but a meaningful minority do, and the risk is higher with daily use, high-potency products, adolescent initiation, and co-occurring mental health conditions. If cannabis is causing problems in your life and you can't stop on your own, that is exactly what evidence-based treatment is for — and it works better than the internet usually admits.
Sources
- Book American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). American Psychiatric Publishing.
- Peer-reviewed Hasin, D. S., Saha, T. D., Kerridge, B. T., et al. (2015). Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12), 1235–1242.
- Peer-reviewed Hall, W., & Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. The Lancet, 374(9698), 1383–1391.
- Peer-reviewed Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016). Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews, (5), CD005336.
- Peer-reviewed Imtiaz, S., Roerecke, M., Kurdyak, P., et al. (2020). Brief interventions for cannabis use in healthcare settings: Systematic review and meta-analyses of randomized trials. Journal of Addiction Medicine, 14(1), 78–88.
- Peer-reviewed Gray, K. M., Carpenter, M. J., Baker, N. L., et al. (2012). A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. American Journal of Psychiatry, 169(8), 805–812.
- Peer-reviewed Gray, K. M., Sonne, S. C., McClure, E. A., et al. (2017). A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence, 177, 249–257.
- Peer-reviewed Mason, B. J., Crean, R., Goodell, V., et al. (2012). A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37(7), 1689–1698.
- Peer-reviewed Brezing, C. A., & Levin, F. R. (2018). The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology, 43(1), 173–194.
- Peer-reviewed Freeman, T. P., Hindocha, C., Baio, G., et al. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry, 7(10), 865–874.
- Peer-reviewed Petrilli, K., Ofori, S., Hines, L., et al. (2022). Association of cannabis potency with mental ill health and addiction: a systematic review. The Lancet Psychiatry, 9(9), 736–750.
- Peer-reviewed Bonnet, U., & Preuss, U. W. (2017). The cannabis withdrawal syndrome: current insights. Substance Abuse and Rehabilitation, 8, 9–37.
- Peer-reviewed Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI). The Lancet Psychiatry, 6(5), 427–436.
- Peer-reviewed Scott, J. C., Slomiak, S. T., Jones, J. D., et al. (2018). Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry, 75(6), 585–595.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.